CLATAZEV
DEAD

Serial Number

90536106

Owner

BRISTOL-MYERS SQUIBB COMPANY

Attorney

Marilyn F. Kelly

Filing Date

Feb 19, 2021

Add to watchlist:

No watchlists yet
View on USPTO

CLATAZEV Trademark

Serial Number: 90536106

CLATAZEV is a trademark filed by BRISTOL-MYERS SQUIBB COMPANY on February 19, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BRISTOL-MYERS SQUIBB COMPANY (4,799 trademarks)

NEW YORK, NY 10154

Entity Type: 03

Trademark Details

Filing Date

February 19, 2021

Registration Date

Not Registered

Published for Opposition

April 12, 2022

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jul 14, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jul 14, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 26, 2025 EXRA
SOU EXTENSION 5 GRANTED
Mar 25, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 25, 2025 AITU
SOU EXTENSION 5 FILED
Nov 25, 2024 EXT5
SOU TEAS EXTENSION RECEIVED
Nov 25, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 21, 2024 EXRA
SOU EXTENSION 4 GRANTED
May 20, 2024 EX4G
SOU EXTENSION 4 FILED
May 20, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
May 20, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 29, 2023 EXRA
SOU EXTENSION 3 GRANTED
Nov 27, 2023 EX3G
SOU EXTENSION 3 FILED
Nov 27, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 27, 2023 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 2, 2023 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 1, 2023 EXRA
SOU EXTENSION 2 GRANTED
May 30, 2023 EX2G
SOU EXTENSION 2 FILED
May 30, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
May 30, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 30, 2022 EXRA
SOU EXTENSION 1 GRANTED
Nov 28, 2022 EX1G
SOU EXTENSION 1 FILED
Nov 28, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 28, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 7, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 12, 2022 NPUB
PUBLISHED FOR OPPOSITION
Apr 12, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 23, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 8, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 8, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 8, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 8, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 8, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 4, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 4, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 4, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 15, 2021 GNRN
NON-FINAL ACTION E-MAILED
Sep 15, 2021 GNRT
NON-FINAL ACTION WRITTEN
Sep 15, 2021 CNRT
ASSIGNED TO EXAMINER
Sep 14, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 21, 2021 NWOS
NEW APPLICATION ENTERED
Feb 23, 2021 NWAP